Preview Mode Links will not work in preview mode

Jul 30, 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Drs Jeremy Abramson, Bruce D Cheson, Ann S LaCasce, Noopur Raje, Paul G Richardson and Sonali M Smith.

  • Introduction
    • Program overview: Dr Love 0m0s
  • Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM) — Dr Raje and Dr Richardson
    • Newly Diagnosed Disease (1:21)
    • Case (Dr Raje): A man in his early 80s with smoldering MM who was observed for 4 years before requiring treatment (5:20)
    • Case (Dr Richardson): A woman in her mid-70s with symptomatic high-risk MM who received RVD followed by bortezomib/dexamethasone maintenance (26:02)
    • Relapsed/Refractory Disease (34:45)
  • Chronic Lymphocytic Leukemia and Follicular Lymphoma — Dr Cheson and Dr LaCasce
    • Chronic Lymphocytic Leukemia (CLL) (53:39)
    • Case (Dr LaCasce): A man in his early 90s with progressive CLL who discontinued treatment with ibrutinib because of poor tolerability and was switched to venetoclax (1:05:17)
    • Case (Dr Cheson): A man in his mid-60s with multiply relapsed CLL who attained a complete response to venetoclax/rituximab (1:07:52)
    • Follicular Lymphoma (FL) (1:18:04)
    • Case (Dr Cheson): A man in his early 60s with newly diagnosed FL who refused chemotherapy and received lenalidomide/rituximab (1:24:58)
    • Case (Dr LaCasce): A man in his late 40s with relapsed FL who received bendamustine/obinutuzumab and attained a complete remission (1:25:40)
    • Case (Dr LaCasce): A woman in her mid-70s with bulky Grade IIIA FL who received R-CHOP (1:34:52)
  • Hodgkin and Other Lymphomas — Dr Abramson and Dr Smith
    • Hodgkin Lymphoma (HL) (1:37:29)
    • Case (Dr Smith): A man in his early 20s with Stage IVB classical HL who received brentuximab vedotin/AVD and remains in remission 1 year later (1:46:29)
    • Mantle Cell Lymphoma (MCL) (1:57:48)
    • Case (Dr Abramson): A man in his early 60s with MCL who has received multiple lines of therapy, including chemotherapy followed by transplant, acalabrutinib and venetoclax (2:02:17)
    • Diffuse Large B-Cell Lymphoma (DLBCL) (2:14:34)
    • Case (Dr Smith): A man in his early 50s with heavily pretreated DLBCL who received chimeric antigen receptor T-cell therapy on a clinical trial (2:14:42)

CME information and select publications